VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 140 filers reported holding VIRIDIAN THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 1.77 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $22,767,500 | +871.2% | 1,750,000 | +1207.2% | 1.76% | +616.7% |
| Q1 2024 | $2,344,186 | -82.3% | 133,877 | -78.0% | 0.24% | -83.3% |
| Q4 2023 | $13,240,389 | +23.4% | 607,915 | -13.1% | 1.47% | -16.5% |
| Q3 2023 | $10,733,107 | -36.4% | 699,681 | -1.4% | 1.76% | -24.4% |
| Q2 2023 | $16,878,957 | +22.1% | 709,498 | +30.5% | 2.32% | +30.1% |
| Q1 2023 | $13,829,260 | -54.2% | 543,603 | -47.5% | 1.78% | -61.5% |
| Q4 2022 | $30,223,499 | +47.4% | 1,034,697 | +3.5% | 4.64% | +7.3% |
| Q3 2022 | $20,510,000 | +200.4% | 1,000,000 | +69.5% | 4.32% | +147.8% |
| Q2 2022 | $6,828,000 | -37.4% | 590,143 | +0.1% | 1.74% | -50.7% |
| Q1 2022 | $10,906,000 | +91.6% | 589,826 | +104.8% | 3.54% | +16.3% |
| Q4 2021 | $5,692,000 | – | 287,934 | – | 3.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TCG Crossover Management, LLC | 1,314,000 | $15,203,000 | 6.46% |
| Ally Bridge Group (NY) LLC | 496,012 | $5,739,000 | 5.23% |
| VR Adviser, LLC | 1,852,919 | $21,438,000 | 4.22% |
| COMMODORE CAPITAL LP | 1,638,609 | $18,959,000 | 4.01% |
| Ghost Tree Capital, LLC | 600,000 | $6,942,000 | 3.62% |
| Paradigm Biocapital Advisors LP | 1,306,569 | $15,117,000 | 3.01% |
| Fairmount Funds Management LLC | 944,092 | $10,923,000 | 2.50% |
| Kynam Capital Management, LP | 590,143 | $6,828,000 | 1.74% |
| Soleus Capital Management, L.P. | 841,018 | $9,731,000 | 1.52% |
| Vivo Capital, LLC | 1,300,000 | $15,041,000 | 1.51% |